[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603152":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":34,"locations":40,"responsibleParty":56,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":81,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Qualia Life Sciences","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Qualia NAD⁺ version 1","ACTIVE_COMPARATOR",null,[13],"Dietary Supplement: Qualia NAD⁺ version 1",{"label":15,"type":10,"description":11,"interventionNames":16},"Qualia NAD⁺ version 2",[17],"Dietary Supplement: Qualia NAD⁺ version 2",{"label":19,"type":20,"description":11,"interventionNames":21},"Placebo","PLACEBO_COMPARATOR",[22],"Dietary Supplement: Placebo",[24,28,31],{"type":25,"name":9,"description":26,"armGroupLabels":27,"otherNames":11},"DIETARY_SUPPLEMENT","Qualia NAD+ version 1 manufactured by Qualia Life Sciences",[9],{"type":25,"name":15,"description":29,"armGroupLabels":30,"otherNames":11},"Qualia NAD+ version 2 manufactured by Qualia Life Sciences",[15],{"type":25,"name":19,"description":32,"armGroupLabels":33,"otherNames":11},"Rice Flour",[19],[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"William Scuba","CONTACT","855-281-2328","support@qualialife.com",[41],{"facility":5,"status":11,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Carlsbad","California","92011","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-117.35059,33.15809,{"lat":51,"lon":50},[54],{"name":55,"role":37,"phone":38,"phoneExt":11,"email":39},"Abhi Ardagh",{"type":57,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100603152","comparison-of-two-qualia-nad-formulations-on-intracellular-nad-levels-100603152",false,"NCT07132801","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial","Inclusion Criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.\n\nHealthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks\u002Fshots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study\n\nExclusion Criteria:\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent",true,"ALL","35 Years","75 Years",{"count":70,"type":71},180,"ESTIMATED","INTERVENTIONAL",[74],"NA","This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.",[77,78],"NAD","NAD+ Levels in the Blood",[80,77],"NAD Supplementation","NOT_YET_RECRUITING","2025-08-13",{"date":84,"type":85},"2025-08-20","ACTUAL",{"date":87,"type":71},"2025-10-13",{"date":89,"type":71},"2025-12-15",{"name":5,"class":6},1]